Benefit-Risk Assessment Methods in Medical Product Development

Benefit-Risk Assessment Methods in Medical Product Development
Author :
Publisher : CRC Press
Total Pages : 296
Release :
ISBN-10 : 9781482259377
ISBN-13 : 1482259370
Rating : 4/5 (77 Downloads)

Book Synopsis Benefit-Risk Assessment Methods in Medical Product Development by : Qi Jiang

Download or read book Benefit-Risk Assessment Methods in Medical Product Development written by Qi Jiang and published by CRC Press. This book was released on 2017-12-19 with total page 296 pages. Available in PDF, EPUB and Kindle. Book excerpt: Guides You on the Development and Implementation of B–R Evaluations Benefit–Risk Assessment Methods in Medical Product Development: Bridging Qualitative and Quantitative Assessments provides general guidance and case studies to aid practitioners in selecting specific benefit–risk (B–R) frameworks and quantitative methods. Leading experts from industry, regulatory agencies, and academia present practical examples, lessons learned, and best practices that illustrate how to conduct structured B–R assessment in clinical development and regulatory submission. The first section of the book discusses the role of B–R assessments in medicine development and regulation, the need for both a common B–R framework and patient input into B–R decisions, and future directions. The second section focuses on legislative and regulatory policy initiatives as well as decisions made at the U.S. FDA’s Center for Devices and Radiological Health. The third section examines key elements of B–R evaluations in a product’s life cycle, such as uncertainty evaluation and quantification, quantifying patient B–R trade-off preferences, ways to identify subgroups with the best B–R profiles, and data sources used to assist B–R assessment. The fourth section equips practitioners with tools to conduct B–R evaluations, including assessment methodologies, a quantitative joint modeling and joint evaluation framework, and several visualization tools. The final section presents a rich collection of case studies. With top specialists sharing their in-depth knowledge, thought-provoking considerations, and practical advice, this book offers comprehensive coverage of B–R evaluation methods, tools, and case studies. It gives practitioners a much-needed toolkit to develop and conduct their own B–R evaluations.


Benefit-Risk Assessment Methods in Medical Product Development Related Books

Benefit-Risk Assessment Methods in Medical Product Development
Language: en
Pages: 296
Authors: Qi Jiang
Categories: Mathematics
Type: BOOK - Published: 2017-12-19 - Publisher: CRC Press

DOWNLOAD EBOOK

Guides You on the Development and Implementation of B–R Evaluations Benefit–Risk Assessment Methods in Medical Product Development: Bridging Qualitative and
Benefit-Risk Assessment Methods in Medical Product Development
Language: en
Pages: 296
Authors: Taylor & Francis Group
Categories:
Type: BOOK - Published: 2020-12-18 - Publisher: CRC Press

DOWNLOAD EBOOK

Guides You on the Development and Implementation of B-R Evaluations Benefit-Risk Assessment Methods in Medical Product Development: Bridging Qualitative and Qua
Managing the Risks from Medical Product Use
Language: en
Pages: 24
Authors: United States. Food and Drug Administration. Task Force on Risk Management
Categories: Medical instruments and apparatus
Type: BOOK - Published: 1999 - Publisher:

DOWNLOAD EBOOK

Pharmacoepidemiology
Language: en
Pages: 1220
Authors: Brian L. Strom
Categories: Medical
Type: BOOK - Published: 2019-12-16 - Publisher: John Wiley & Sons

DOWNLOAD EBOOK

This classic, field-defining textbook, now in its sixth edition, provides the most comprehensive guidance available for anyone needing up-to-date information in
Benefit-Risk Assessment in Pharmaceutical Research and Development
Language: en
Pages: 222
Authors: Andreas Sashegyi
Categories: Mathematics
Type: BOOK - Published: 2013-11-27 - Publisher: CRC Press

DOWNLOAD EBOOK

Many practitioners in the pharmaceutical industry are still largely unfamiliar with benefit-risk assessment, despite its growing prominence in drug development